A photo of Cuixia Tian.

Cuixia Tian, MD


  • Director MDA Clinic and PPMD Certified DMD Clinic, Division of Neurology
  • Neuromuscular Disease Specialist, Division of Neurology
  • Associate Professor, UC Department of Pediatrics
My team and I are focused on families' concerns and work together to provide the best care possible to our patients.
Cuixia Tian, MD

About

Biography

I'm a board-certified child neurologist who specializes in neuromuscular diseases. I am co-director of the multidisciplinary comprehensive neuromuscular care program and serve as the program's neurology lead. I'm also the clinical director of the Parent Project Muscular Dystrophy (PPMD) Certified Duchenne Muscular Dystrophy (DMD) Clinic and clinical director of the Muscular Dystrophy Association (MDA) Care Center.

My mom was a devoted elementary teacher, loved by many of her students. Her love for children inspired me, and I became a pediatrician. I am honored to be recognized by Cincinnati Magazine’s Top Doctors in Pediatric Neurology (2023).

I'm passionate about caring for children and young adults with chronic neuromuscular disease. I love meeting families and listening to parents advocating for their children. My team and I are focused on families' concerns and work together to provide the best care possible to our patients.

As a clinical researcher, I actively lead and collaborate on multiple clinical trials and research studies in pediatric neuromuscular diseases to develop advanced therapies and improve clinical care for our patients.

When I'm not at work, I love music and the arts. I also enjoy gardening and playing tennis.

MD: Medical Center of Fudan University, Shanghai, China, 1993.

Residency: Cincinnati Children’s Hospital Medical Center.

Myology Institute Clinical Myology Training; Paris, France, 2014.

Wellstone Myology Training; Ohio State University, Columbus, OH, 2013.

World Muscle Society Satellite Training; Asilomar, California, 2013.

Services and Specialties

Neurology

Additional Languages

Chinese

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy. Muntoni, F; Byrne, BJ; McMillan, HJ; Ryan, MM; Wong, BL; Dukart, J; Bansal, A; Cosson, V; Dreghici, R; Guridi, M; et al. Neurology and Therapy. 2024; 13:183-219.

Appendicular lean mass index changes in patients with Duchenne muscular dystrophy and Becker muscular dystrophy. Wong, BL; Summer, S; Horn, PS; Rutter, MM; Rybalsky, I; Tian, C; Shellenbarger, KC; Kalkwarf, HJ. Journal of Cachexia, Sarcopenia and Muscle. 2023; 14:2804-2812.

An evaluation of clinical presentation and genetic testing approaches for patients with neuromuscular disorders. Rosenberg, A; Tian, C; He, H; Ulm, E; Collins Ruff, K; B. Nagaraj, C. American Journal of Medical Genetics, Part A. 2023; 191:2679-2692.

P249 Early onset dilated cardiomyopathy in a 6-year-old boy with Duchenne muscular dystrophy. Zygmunt, A; Villa, C; Ryan, T; Nagaraj, CB; Rybalsky, I; Reebals, L; Tian, C. Neuromuscular Disorders. 2023; 33:s177.

P253 Motor function and genotype-phenotype correlations in paediatric Becker muscular dystrophy. Zygmunt, A; Shiuan, Y; Horn, P; Rybalsky, I; Reebals, L; Tian, C. Neuromuscular Disorders. 2023; 33:s146.

P258 Clinical profile of Duchenne muscular dystrophy associated with in-frame deletions in DMD. Zygmunt, A; Horn, P; Rybalsky, I; Reebals, L; Bange, J; Tian, C. Neuromuscular Disorders. 2023; 33:s147.

P356 Novel TBCK variant and expanded clinical phenotype. Nagaraj, CB; Reebals, L; Broomall, E; Tian, C. Neuromuscular Disorders. 2023; 33:s184.

Use of supported standing in males with Duchenne muscular dystrophy: Individual and family perspectives. Bonarrigo, K; McGuire, M; Dorich, JM; Bolger, A; Lambert, J; Horn, PS; Tian, C. Journal of Pediatric Rehabilitation Medicine. 2023; 16:553-569.

Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy. Connolly, AM; Zaidman, CM; Brandsema, JF; Phan, HC; Tian, C; Zhang, X; Li, J; Eisner, MD; Carrier, E. Journal of Neuromuscular Diseases. 2023; 10:685-699.

Obesity and loss of ambulation are associated with lower extremity oedema in Duchenne muscular dystrophy. Freytag, JM; Ryan, TD; Bange, JE; Bonarrigo, KC; Chouteau, WA; Wittekind, SG; Tian, C; Gao, Z; Villa, CR. Cardiology in the Young. 2023; 33:597-602.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating